Novartis Ag (NVSEF) Retained Earnings (2009 - 2025)

Novartis Ag has disclosed Retained Earnings across 11 years of filings, most recently posting $45.4 billion for Q4 2025.

• Retained Earnings for Q4 2025 came in at $45.4 billion, up 4.87% year-over-year; the trailing twelve-month figure through Dec 2025 was $45.4 billion (up 4.87% YoY), and the FY2025 annual result was $45.4 billion, up 4.87% from the prior year.
• Retained Earnings came in at $45.4 billion for Q4 2025 at Novartis Ag, up from $41.3 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $66.8 billion in Q4 2021 to a low of $41.0 billion in Q2 2024.
• The 5-year median for Retained Earnings is $48.5 billion (2023), against an average of $50.9 billion.
• Across the five-year window, Retained Earnings climbed 19.85% in 2021 and fell 21.63% in 2023, its largest moves.
• Novartis Ag's Retained Earnings stood at $66.8 billion in 2021, then dropped by 12.36% to $58.5 billion in 2022, then dropped by 21.63% to $45.9 billion in 2023, then dropped by 5.62% to $43.3 billion in 2024, then grew by 4.87% to $45.4 billion in 2025.
• The last three Retained Earnings figures came in at $45.4 billion (Q4 2025), $41.3 billion (Q2 2025), and $43.3 billion (Q4 2024), per Business Quant data.